- Home
- CPBI vs ATYR Comparison
CPBI vs ATYR Comparison
Compare CPBI & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CPBI | ATYR |
|---|---|---|
| Founded | 2023 | 2005 |
| Country | United States | United States |
| Employees | N/A | 58 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.5M | 73.7M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | CPBI | ATYR |
|---|---|---|
| Price | $17.31 | $0.80 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $3.67 |
| AVG Volume (30 Days) | 4.1K | ★ 939.9K |
| Earning Date | 06-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.10 | $0.64 |
| 52 Week High | $17.89 | $7.29 |
Technical Indicators
Market Signals| Indicator | CPBI | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 51.77 | 44.45 |
| Support Level | $17.37 | $0.68 |
| Resistance Level | $17.88 | $0.85 |
| Average True Range (ATR) | 0.31 | 0.05 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 51.28 | 48.87 |
Price Performance
Historical ComparisonAbout CPBI Central Plains Bancshares Inc.
Central Plains Bancshares Inc operates as the bank holding company for Home Federal Savings and Loan Association of Grand Island that provides mortgage, consumer, commercial real estate, and commercial loans, The bank business consists mainly of accepting deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential mortgage loans secured by properties located in primary market area, as well as commercial real estate loans.
About ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).